For a copy of this analyst report please contact your CLSA advisor
October 4th 2022
analyst reports
October 4th 2022
analyst reports
October 4th 2022
press releases
September 26th 2022
press releases
September 23rd 2022
press releases
This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.
September 15th 2022
analyst reports
Upcoming Events
What's next.
November 8th 2022 - November 10th 2022
read more
November 15th 2022 - November 17th 2022
read more
passion.
It takes a great deal of passion to pursue the fight against cancer and autoimmune diseases. We put our heart and soul into winning it.
know-how.
Our goal is to gather the strongest forces, the brightest minds and the most dedicated employees.
research.
Accurate research and development is the strongest foundation for developing effective treatments.
What is LAG-3?
Lymphocyte-activation gene 3, or LAG-3 (LAG-3), is a gene that provides the genetic information to make a cell surface molecule with biologic effects on T cell function.
LAG-3 is being used for many immunotherapy treatments including Eftilagimod Alpha from Immutep.
